Quest Diagnostics Incorporated (NYSE:DGX)‘s stock had its “market perform” rating reissued by stock analysts at Raymond James Financial, Inc. in a research note issued on Monday.
DGX has been the subject of a number of other reports. Zacks Investment Research upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $122.00 price objective for the company in a report on Tuesday, June 6th. BidaskClub upgraded shares of Quest Diagnostics from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 29th. Barclays PLC reiterated a “hold” rating and issued a $110.00 price objective on shares of Quest Diagnostics in a report on Wednesday, July 19th. ValuEngine upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Friday, June 2nd. Finally, Mizuho upped their price objective on shares of Quest Diagnostics from $115.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, June 5th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $111.09.
Quest Diagnostics (NYSE:DGX) opened at 102.11 on Monday. The company has a 50-day moving average price of $106.58 and a 200-day moving average price of $105.42. The firm has a market cap of $13.93 billion, a PE ratio of 20.58 and a beta of 0.69. Quest Diagnostics has a one year low of $79.12 and a one year high of $112.97.
Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $1.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.42 by $0.13. The firm had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. Quest Diagnostics had a net margin of 9.28% and a return on equity of 15.66%. Quest Diagnostics’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.34 earnings per share. Equities analysts predict that Quest Diagnostics will post $5.69 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://ledgergazette.com/2017/09/25/quest-diagnostics-incorporated-dgx-receives-market-perform-rating-from-raymond-james-financial-inc.html.
In related news, Director Jeffrey M. Leiden sold 1,304 shares of the stock in a transaction dated Thursday, July 27th. The shares were sold at an average price of $108.73, for a total value of $141,783.92. Following the completion of the transaction, the director now owns 6,296 shares of the company’s stock, valued at $684,564.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Stephen H. Rusckowski sold 59,235 shares of the stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $108.16, for a total transaction of $6,406,857.60. Following the completion of the transaction, the chairman now directly owns 220,049 shares of the company’s stock, valued at approximately $23,800,499.84. The disclosure for this sale can be found here. Insiders sold 161,996 shares of company stock valued at $17,517,207 in the last three months. Company insiders own 1.75% of the company’s stock.
A number of large investors have recently bought and sold shares of DGX. UBS Asset Management Americas Inc. raised its position in Quest Diagnostics by 39.6% in the first quarter. UBS Asset Management Americas Inc. now owns 622,554 shares of the medical research company’s stock worth $61,129,000 after purchasing an additional 176,609 shares in the last quarter. Keybank National Association OH grew its stake in Quest Diagnostics by 2.8% during the first quarter. Keybank National Association OH now owns 3,089 shares of the medical research company’s stock worth $303,000 after buying an additional 85 shares during the last quarter. Baird Financial Group Inc. grew its stake in Quest Diagnostics by 4.2% during the first quarter. Baird Financial Group Inc. now owns 3,122 shares of the medical research company’s stock worth $307,000 after buying an additional 125 shares during the last quarter. Martingale Asset Management L P bought a new stake in Quest Diagnostics during the first quarter worth about $474,000. Finally, Shufro Rose & Co. LLC grew its stake in Quest Diagnostics by 4.1% during the first quarter. Shufro Rose & Co. LLC now owns 9,865 shares of the medical research company’s stock worth $969,000 after buying an additional 385 shares during the last quarter. 87.10% of the stock is owned by hedge funds and other institutional investors.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.